ARVN Q4 2024 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+237.4% YoY

Gross Profit

$59M100.0% margin

Operating Income

-$58M-98.3% margin

Net Income

-$45M-76.2% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-42.2%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$84M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$530M

Stockholders' Equity

$562M

Cash & Equivalents

$101M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	-$43M	+237.4%
Gross Profit	$59M	-$45M	+232.1%
Operating Income	-$58M	-$165M	+64.8%
Net Income	-$45M	-$155M	+70.9%